MA32968B1 - Composes quinazoline substitues - Google Patents
Composes quinazoline substituesInfo
- Publication number
- MA32968B1 MA32968B1 MA34018A MA34018A MA32968B1 MA 32968 B1 MA32968 B1 MA 32968B1 MA 34018 A MA34018 A MA 34018A MA 34018 A MA34018 A MA 34018A MA 32968 B1 MA32968 B1 MA 32968B1
- Authority
- MA
- Morocco
- Prior art keywords
- methods
- kinase
- disorder
- substituted quinazoline
- compounds
- Prior art date
Links
- 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 5
- 238000000034 method Methods 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000017442 Retinal disease Diseases 0.000 abstract 1
- 206010038923 Retinopathy Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 229940043355 kinase inhibitor Drugs 0.000 abstract 1
- 208000002780 macular degeneration Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical class N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08360043 | 2008-12-29 | ||
| PCT/EP2009/067494 WO2010076238A1 (en) | 2008-12-29 | 2009-12-18 | Substituted quinazoline compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA32968B1 true MA32968B1 (fr) | 2012-01-02 |
Family
ID=41735344
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA34018A MA32968B1 (fr) | 2008-12-29 | 2009-12-18 | Composes quinazoline substitues |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US8389530B2 (https=) |
| EP (1) | EP2381943A1 (https=) |
| JP (1) | JP2012514020A (https=) |
| KR (1) | KR20110120878A (https=) |
| CN (1) | CN102333533A (https=) |
| AU (1) | AU2009334869A1 (https=) |
| BR (1) | BRPI0924067A2 (https=) |
| CA (1) | CA2748319A1 (https=) |
| CO (1) | CO6390105A2 (https=) |
| CR (1) | CR20110368A (https=) |
| DO (1) | DOP2011000209A (https=) |
| EA (1) | EA019110B1 (https=) |
| EC (1) | ECSP11011204A (https=) |
| IL (1) | IL213742A0 (https=) |
| MA (1) | MA32968B1 (https=) |
| MX (1) | MX2011007064A (https=) |
| NI (1) | NI201100134A (https=) |
| NZ (1) | NZ593949A (https=) |
| PE (1) | PE20120424A1 (https=) |
| SG (1) | SG172415A1 (https=) |
| TN (1) | TN2011000319A1 (https=) |
| WO (1) | WO2010076238A1 (https=) |
| ZA (1) | ZA201104777B (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR081960A1 (es) | 2010-06-22 | 2012-10-31 | Fovea Pharmaceuticals Sa | Compuestos heterociclicos, su preparacion y su aplicacion terapeutica |
| SMT202100451T1 (it) | 2012-07-11 | 2021-09-14 | Blueprint Medicines Corp | Inibitori del recettore di crescita dei fibroblasti |
| CA2928042C (en) | 2013-10-25 | 2022-05-10 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
| WO2015108992A1 (en) | 2014-01-15 | 2015-07-23 | Blueprint Medicines Corporation | Heterobicyclic compounds and their use as fgfr4 receptor inhibitors |
| KR101715448B1 (ko) * | 2014-07-16 | 2017-03-20 | 주식회사 큐리언트 | 염증성 질환 치료용 화합물 |
| TWI699355B (zh) | 2014-12-24 | 2020-07-21 | 美商基利科學股份有限公司 | 喹唑啉化合物 |
| BR112017013440A2 (pt) | 2014-12-24 | 2018-01-09 | Gilead Sciences, Inc. | compostos de isoquinolina para o tratamento de hiv |
| ES2735087T3 (es) | 2014-12-24 | 2019-12-16 | Gilead Sciences Inc | Compuestos de pirimidina fusionados para el tratamiento de VIH |
| CN112239459B (zh) * | 2019-07-19 | 2021-11-26 | 中国科学院上海药物研究所 | 稠环嘧啶氨基化合物、其制备方法、药物组合物及应用 |
| CN115916759B (zh) * | 2020-06-19 | 2025-07-15 | 泰州红云制药有限公司 | 取代喹唑啉类化合物、其制备方法、药物组合及应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2386955A1 (en) * | 1999-11-22 | 2001-05-31 | Warner-Lambert Company | Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes |
| EP1590341B1 (en) | 2003-01-17 | 2009-06-17 | Warner-Lambert Company LLC | 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation |
| CN1882345A (zh) | 2003-10-16 | 2006-12-20 | 希龙公司 | 作为raf激酶抑制剂以治疗癌症的2,6－二取代的喹唑啉、喹喔啉、喹啉和异喹啉 |
| KR20070011458A (ko) | 2004-04-08 | 2007-01-24 | 탈자진 인코포레이티드 | 키나제의 벤조트리아진 억제제 |
| PL382308A1 (pl) | 2004-08-25 | 2007-08-20 | Targegen, Inc. | Związki heterocykliczne i sposoby stosowania |
| US20070054916A1 (en) | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| US20060247250A1 (en) | 2005-03-16 | 2006-11-02 | Targegen, Inc. | Pyrimidine inhibitors of kinases |
| JP5079500B2 (ja) * | 2005-04-28 | 2012-11-21 | 協和発酵キリン株式会社 | ２−アミノキナゾリン誘導体 |
| NZ563984A (en) | 2005-06-08 | 2011-11-25 | Targegen Inc | Methods and compositions for the treatment of ocular disorders |
| TW200808739A (en) * | 2006-04-06 | 2008-02-16 | Novartis Vaccines & Diagnostic | Quinazolines for PDK1 inhibition |
| CA2673003A1 (en) * | 2006-12-22 | 2008-07-03 | Novartis Ag | Quinazolines for pdk1 inhibition |
-
2009
- 2009-12-18 AU AU2009334869A patent/AU2009334869A1/en not_active Abandoned
- 2009-12-18 CN CN2009801575427A patent/CN102333533A/zh active Pending
- 2009-12-18 CA CA2748319A patent/CA2748319A1/en not_active Abandoned
- 2009-12-18 EA EA201101012A patent/EA019110B1/ru not_active IP Right Cessation
- 2009-12-18 PE PE2011001296A patent/PE20120424A1/es not_active Application Discontinuation
- 2009-12-18 WO PCT/EP2009/067494 patent/WO2010076238A1/en not_active Ceased
- 2009-12-18 JP JP2011544017A patent/JP2012514020A/ja active Pending
- 2009-12-18 EP EP09799340A patent/EP2381943A1/en not_active Withdrawn
- 2009-12-18 SG SG2011047339A patent/SG172415A1/en unknown
- 2009-12-18 BR BRPI0924067A patent/BRPI0924067A2/pt not_active IP Right Cessation
- 2009-12-18 MA MA34018A patent/MA32968B1/fr unknown
- 2009-12-18 NZ NZ593949A patent/NZ593949A/xx not_active IP Right Cessation
- 2009-12-18 MX MX2011007064A patent/MX2011007064A/es active IP Right Grant
- 2009-12-18 KR KR1020117017495A patent/KR20110120878A/ko not_active Withdrawn
- 2009-12-18 US US13/142,333 patent/US8389530B2/en not_active Expired - Fee Related
-
2011
- 2011-06-23 IL IL213742A patent/IL213742A0/en unknown
- 2011-06-27 TN TN2011000319A patent/TN2011000319A1/fr unknown
- 2011-06-27 CR CR20110368A patent/CR20110368A/es not_active Application Discontinuation
- 2011-06-28 ZA ZA2011/04777A patent/ZA201104777B/en unknown
- 2011-06-29 DO DO2011000209A patent/DOP2011000209A/es unknown
- 2011-06-29 NI NI201100134A patent/NI201100134A/es unknown
- 2011-06-29 CO CO11081323A patent/CO6390105A2/es not_active Application Discontinuation
- 2011-07-14 EC EC2011011204A patent/ECSP11011204A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NZ593949A (en) | 2013-08-30 |
| TN2011000319A1 (en) | 2012-12-17 |
| ZA201104777B (en) | 2012-03-28 |
| US20120004210A1 (en) | 2012-01-05 |
| BRPI0924067A2 (pt) | 2016-01-26 |
| CA2748319A1 (en) | 2010-07-08 |
| AU2009334869A2 (en) | 2011-09-29 |
| IL213742A0 (en) | 2011-07-31 |
| SG172415A1 (en) | 2011-07-28 |
| EA019110B1 (ru) | 2014-01-30 |
| CO6390105A2 (es) | 2012-02-29 |
| WO2010076238A1 (en) | 2010-07-08 |
| JP2012514020A (ja) | 2012-06-21 |
| MX2011007064A (es) | 2012-01-20 |
| CR20110368A (es) | 2011-12-02 |
| AU2009334869A1 (en) | 2011-07-14 |
| PE20120424A1 (es) | 2012-05-04 |
| ECSP11011204A (es) | 2011-10-31 |
| EA201101012A1 (ru) | 2012-01-30 |
| US8389530B2 (en) | 2013-03-05 |
| DOP2011000209A (es) | 2011-09-30 |
| KR20110120878A (ko) | 2011-11-04 |
| CN102333533A (zh) | 2012-01-25 |
| NI201100134A (es) | 2012-03-06 |
| EP2381943A1 (en) | 2011-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA32968B1 (fr) | Composes quinazoline substitues | |
| FR21C1031I2 (fr) | Derives de la n4-phenyl-quinazoline-4-amine et composes similaires en tant que inhibiteurs de la kinase tyrosine erbb type i pour le traitement de maladies hyperproliferatives | |
| CY1122238T1 (el) | Νεα 1-ναφθυλ-3-αζαδικυκλο[3.1.0]εξανia: παρασκευη και χρηση για τη θεραπεια νευροψυχιατρικων διαταραχων | |
| UA116614C2 (uk) | Антитіло до фактора d і його застосування | |
| ATE528302T1 (de) | 3,5-disubstituierte pyrid-2-one, die als hemmer der tec-familie von nicht-rezeptor tyrosin- kinasen nützlich sind | |
| MA31999B1 (fr) | Proteines de liaison a l'antigene | |
| ATE548363T1 (de) | 3,5-disubstituierte pyrid-2-one, die sich als inhibitoren der tec-familie von nicht-rezeptor- tyrosinkinasen eignen | |
| MA33604B1 (fr) | Composés et compositions en tant qu'inhibiteurs de protéine kinase | |
| MA30876B1 (fr) | Anticorps de la lymphotoxine-alpha | |
| JO3346B1 (ar) | مواد مضادة C5aR | |
| NO20091759L (no) | Forbindelser og sammensetninger som protein kinase inhibitorer | |
| MA35460B1 (fr) | Composés et compositions en tant qu'inhibiteurs de kinase c-kit | |
| MA30557B1 (fr) | Composés de pyrrolopyrimidine et leurs utilisations. | |
| CY1117317T1 (el) | Αναστολεις κινασης janus για θεραπεια ξηροφθαλμιας και αλλων σχετικων με τον οφθαλμο ασθενειων | |
| MA32771B1 (fr) | Mutants fgf21 et leurs utilisations | |
| TW200630356A (en) | Polymorphic forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl]indazole | |
| MA33534B1 (fr) | Anticorps humains d'affinité élevée dirigés contre l'angiopoïétine 2 humaine | |
| MY151191A (en) | Novel antibodies | |
| TN2009000323A1 (en) | Modulators of sclerostin binding partners for treating bone-related disorders | |
| MA38076A1 (fr) | Dérivés d'oxazolidin-2-one-pyrimidine | |
| MX2009012625A (es) | Metodos para el tratamiento, diagnostico y deteccion de trastornos asociados con el fgf21. | |
| SG166827A1 (en) | Aminopyrimidines useful as kinase inhibitors | |
| NO20090268L (no) | Benzofuro- and benzothienopyrimidine modulators of the histamine H4 receptor | |
| MA47392A1 (fr) | Bis-octahydrophénanthrène carboxamides et leurs conjugués protéiques | |
| MX368459B (es) | Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central. |